



Express Mail No. EV 687 637 660 US

INFORMATION DISCLOSURE STATEMENT		
Address to:	Attorney Docket	DURE-007CON2
Mail Stop	First Named Inventor	JOHNSON, RANDOLPH MELLUS
Commissioner for Patents	Application Number	10/719,007
P.O. Box 1450	Confirmation No.	9101
Alexandria, VA 22313-1450	Filing Date	November 20, 2003
	Group Art Unit	1615
	Examiner Name	Ghali, Isis A. D.
	Title:	"DEVICES AND METHODS FOR PAIN MANAGEMENT"

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. DURE-007CON2 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

By:


Carol L. Francis
Registration No. 16,513

Date: June 20, 2006

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Do not use this form for a collection of information unless it contains a valid OMB control number.

work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<i>Complete if Known</i>	
				Application Number	10/719,007
				Filing Date	November 20, 2003
				First Named Inventor	JOHNSON, RANDOLPH MELLUS
				Art Unit	1615
				Examiner Name	Ghali, Isis A. D.
				Attorney Docket Number	DURE-007CON2
Sheet	1	of	3		

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁸
		Country Code ³ —Number ⁴ —Kind Code ⁶ (if known)				
		WO 90/077333	07/12/1990	Purewal, et al.		
		WO 95/31182	11/1995	Farr, et al.		
		WO 92/02256	02/1992	Yaksh et al.		
		WO 2004/047839	06/10/2004	Chan, et al.		
		EP 0 267 617 A1	05/1988	Patel et al.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/719,007
				Filing Date	November 20, 2003
				First Named Inventor	JOHNSON, RANDOLPH MELLUS
				Art Unit	1615
				Examiner Name	Ghali, Isis A. D.
Sheet	2	of	3	Attorney Docket Number	DURE-007CON2

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		Fudin et al. "Use of Continuous Ambulatory Infusions of Concentrated Subcutaneous (SQ) hydromorphone versus intravenous (IV) Morphine: Cost Implications for Palliative Care" Am J Hospice Palliative Care 17:347-353 (2000).			
		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Ativan (2001) pp. 821.			
		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Fentanyl (2001) pp. 826.			
		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Meperidine (2001) pp. 828.			
		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Morphine (2001) pp. 830.			
		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Sulfentanil Citrate (2001) pp. 831-32.			
		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Hydroxyzine Hydrochloride (2001) pp. 1193.			
		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Duramorph (2001) pp. 1195-1197.			
		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Duragesic (2001) pp. 1573-1577.			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/719,007
				Filing Date	November 20, 2003
				First Named Inventor	JOHNSON, RANDOLPH MELLUS
				Art Unit	1615
Examiner Name	Ghali, Isis A. D.				
Sheet	3	of	3	Attorney Docket Number	DURE-007CON2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Physician's Desk Reference, Thomson Healthcare, Montvale, NJ, Dilaudid (2001) pp. 1619-1623.	
		Ramsay, et al. "Immobilization of black bears (<i>Ursus americanus</i>) with orally administered carfentanil citrate", Database Biosis Online!, Biosciences Information Service, Philadelphia, PA US, database accession number PREV 100598404995, abstract (1995);	
		Ramsay, et al., "Immobilization of black bears (<i>Ursus americanus</i>) with orally administered carfentanil citrate", Journal of Wildlife Diseases, (1995), 31(3): 391-393	
		Scholz et al. "Clinical Pharmacokinetics of Alfentanil, Fentanyl and Sufentanil" Clin. Pharmacokinet. 31:275-92 (1996).	
		Stephens "Intrathecal Narcotics for Labor Analgesia" Am. Fam. Physician 56:463-70 (1997).	
		Vercauteren et al. "Postoperative Intrathecal Patient-Controlled Analgesia With Bupivacaine, Sufentanil or a mixture of Both" Anaesthesia 53:1022-7 (1998).	
		White "Clinical Uses of Intravenous Anesthetic and Analgesic Infusions" Anesth. Analg. 68:161-171 (1989).	
		Willens et al. "Pharmacodynamics, Pharmacokinetics, and Clinical Uses of Fentanyl, Sufentanil, and Alfentanil" Heart Lung 22:239-52 (1993).	
		Roy and Flynn. "Solubility and Related Physicochemical Properties of Narcotic Analgesics", Pharm Research, 1988, vol. 5, no. 9, pgs 580-586.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.